5,356 reports of this reaction
3.1% of all FINGOLIMOD HCL reports
#4 most reported adverse reaction
DIZZINESS is the #4 most commonly reported adverse reaction for FINGOLIMOD HCL, manufactured by Novartis Pharmaceuticals Corporation. There are 5,356 FDA adverse event reports linking FINGOLIMOD HCL to DIZZINESS. This represents approximately 3.1% of all 175,367 adverse event reports for this drug.
Patients taking FINGOLIMOD HCL who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among FINGOLIMOD HCL users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for FINGOLIMOD HCL:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 5,356 FDA reports for FINGOLIMOD HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 3.1% of all adverse event reports for FINGOLIMOD HCL, making it a notable side effect.
If you experience dizziness while taking FINGOLIMOD HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.